GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » EV-to-EBIT

SomaLogic (SomaLogic) EV-to-EBIT : 0.63 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SomaLogic's Enterprise Value is $-54.82 Mil. SomaLogic's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-86.65 Mil. Therefore, SomaLogic's EV-to-EBIT for today is 0.63.

The historical rank and industry rank for SomaLogic's EV-to-EBIT or its related term are showing as below:

SLGC' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.25   Med: -0.6   Max: 1.38
Current: 0.63

During the past 3 years, the highest EV-to-EBIT of SomaLogic was 1.38. The lowest was -53.25. And the median was -0.60.

SLGC's EV-to-EBIT is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 18.53 vs SLGC: 0.63

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SomaLogic's Enterprise Value for the quarter that ended in Sep. 2023 was $-0.14 Mil. SomaLogic's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-86.65 Mil. SomaLogic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 59,830.13%.


SomaLogic EV-to-EBIT Historical Data

The historical data trend for SomaLogic's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic EV-to-EBIT Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
EV-to-EBIT
- -16.89 0.60

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.60 0.18 0.39 -

Competitive Comparison of SomaLogic's EV-to-EBIT

For the Health Information Services subindustry, SomaLogic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomaLogic's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SomaLogic's EV-to-EBIT falls into.



SomaLogic EV-to-EBIT Calculation

SomaLogic's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-54.821/-86.646
=0.63

SomaLogic's current Enterprise Value is $-54.82 Mil.
SomaLogic's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomaLogic  (NAS:SLGC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SomaLogic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-86.646/-0.14481999999998
=59,830.13 %

SomaLogic's Enterprise Value for the quarter that ended in Sep. 2023 was $-0.14 Mil.
SomaLogic's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomaLogic EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SomaLogic's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (SomaLogic) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director